ArticleTropical medicine and health2026
Antibodies against dengue virus in COVID-19 patients in Japan: a dengue virus non-endemic country.
Article in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was associated with a global pandemic in 2020. Infection and vaccination induced a variety of immune responses in humans that differed from those observed before the pandemic. Several reports indicated that SARS-CoV-2 infection induced the production of antibodies cross-reactive to dengue virus. However, many of these reports emerged from dengue-endemic regions, and the possibility that induction of cross-reactive antibodies was affected by memory immunity induced by previous dengue virus infection could not be ruled out. MAIN TEXT : In the present study, we investigated the levels of cross-reactive antibodies against dengue virus in 118 COVID-19 patients in Japan, a dengue non-endemic country. Serum samples collected from each patient during the acute and convalescent phases were analyzed using commercial IgG and IgM ELISA kits. The analysis revealed two dengue IgM-positive cases in both the acute and convalescent phases of COVID-19. These two cases showed an increasing trend of dengue IgM antibody titer in the convalescent phase. One additional case was dengue IgM-negative in the acute phase and IgM-borderline in the convalescent phase. By contrast, no cases of positive or elevated dengue IgG were observed. All 118 cases investigated in the present study lacked a history of recent travel to dengue-endemic countries. These findings suggest that SARS-CoV-2 infection induces IgM that cross-reacts with dengue virus antigens, even in the absence of immunological memory against dengue virus.
conclusionsCertain COVID-19 patients in Japan produced IgM that cross-reacted with dengue virus. Therefore, the presence of false positives should be considered in the serodiagnosis of dengue fever and COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.